JP2012520852A5 - - Google Patents

Download PDF

Info

Publication number
JP2012520852A5
JP2012520852A5 JP2012500251A JP2012500251A JP2012520852A5 JP 2012520852 A5 JP2012520852 A5 JP 2012520852A5 JP 2012500251 A JP2012500251 A JP 2012500251A JP 2012500251 A JP2012500251 A JP 2012500251A JP 2012520852 A5 JP2012520852 A5 JP 2012520852A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
disease
antigenic composition
antigenic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2012500251A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012520852A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2010/053519 external-priority patent/WO2010106127A2/en
Publication of JP2012520852A publication Critical patent/JP2012520852A/ja
Publication of JP2012520852A5 publication Critical patent/JP2012520852A5/ja
Withdrawn legal-status Critical Current

Links

JP2012500251A 2009-03-18 2010-03-18 治療的使用のための方法 Withdrawn JP2012520852A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US16116509P 2009-03-18 2009-03-18
US61/161,165 2009-03-18
US25602809P 2009-10-29 2009-10-29
US61/256,028 2009-10-29
PCT/EP2010/053519 WO2010106127A2 (en) 2009-03-18 2010-03-18 Method for therapeutic use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015134900A Division JP2015221809A (ja) 2009-03-18 2015-07-06 治療的使用のための方法

Publications (2)

Publication Number Publication Date
JP2012520852A JP2012520852A (ja) 2012-09-10
JP2012520852A5 true JP2012520852A5 (enExample) 2013-04-25

Family

ID=42376556

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012500251A Withdrawn JP2012520852A (ja) 2009-03-18 2010-03-18 治療的使用のための方法
JP2015134900A Pending JP2015221809A (ja) 2009-03-18 2015-07-06 治療的使用のための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015134900A Pending JP2015221809A (ja) 2009-03-18 2015-07-06 治療的使用のための方法

Country Status (17)

Country Link
US (1) US20100285108A1 (enExample)
EP (2) EP2408807B1 (enExample)
JP (2) JP2012520852A (enExample)
KR (1) KR20120004994A (enExample)
CN (1) CN102428101B (enExample)
AU (1) AU2010224824B2 (enExample)
CA (1) CA2755683A1 (enExample)
DK (1) DK2408807T3 (enExample)
ES (1) ES2885398T3 (enExample)
HU (1) HUE055739T2 (enExample)
IL (1) IL214919A (enExample)
MX (1) MX2011009654A (enExample)
PT (1) PT2408807T (enExample)
RU (1) RU2579659C2 (enExample)
SG (1) SG174871A1 (enExample)
SI (1) SI2408807T1 (enExample)
WO (1) WO2010106127A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA107571C2 (xx) * 2009-04-03 2015-01-26 Фармацевтична композиція
CN106390107B (zh) * 2009-06-10 2019-12-31 纽约大学 病理tau蛋白的免疫靶向
AU2013205313B2 (en) * 2010-10-07 2016-05-19 Ac Immune S.A. Phosphospecific antibodies recognising tau
MY164376A (en) * 2010-10-07 2017-12-15 Univ Leuven Kath Phosphospecific antibodies recognizing tau
CA2811188C (en) * 2011-09-23 2020-04-28 Andrea Pfeifer Vaccine therapy
KR101981351B1 (ko) 2011-10-07 2019-09-02 에이씨 이뮨 에스.에이. 타우를 인식하는 포스포특이적 항체
RU2644242C2 (ru) 2012-04-05 2018-02-08 Ац Иммуне С.А. Гуманизированное тау-антитело
CN104428411B (zh) * 2012-05-08 2018-11-23 健康科学西部大学 用于cd4+t细胞群之抗原特异性扩增的标准化离体平台
WO2014150877A2 (en) 2013-03-15 2014-09-25 Ac Immune S.A. Anti-tau antibodies and methods of use
CN107073297B (zh) 2014-07-08 2021-09-14 纽约大学 Tau显像配体和其在Tau蛋白病的诊断和治疗中的用途
RU2689689C2 (ru) * 2015-01-23 2019-05-28 Хеликс Байофарма Корпорейшн Конъюгаты антитело-уреаза для терапевтических целей
WO2017027685A2 (en) 2015-08-13 2017-02-16 New York University Antibody-based molecules specific for the truncated asp421 epitope of tau and their uses in the diagnosis and treatment of tauopathy
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
CN111787942B (zh) 2017-10-25 2024-03-29 杨森制药公司 磷酸化Tau肽的组合物及其用途
WO2020160156A2 (en) 2019-01-30 2020-08-06 Immutics, Inc. Anti-gal3 antibodies and uses thereof
MY206596A (en) 2019-02-08 2024-12-25 Janssen Pharmaceuticals Inc Method of safe administration of phosphorylated tau peptide vaccine
JOP20210284A1 (ar) * 2019-04-24 2023-01-30 Janssen Pharmaceuticals Inc الإعطاء غير المتجانس للقاحات تاو
SG11202112329RA (en) * 2019-05-21 2021-12-30 Ac Immune Sa Anti-abeta vaccine therapy
EP4157338A4 (en) 2020-05-26 2024-11-13 TrueBinding, Inc. METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING
AU2024211543A1 (en) 2023-01-26 2025-07-17 Ac Immune Sa Liposomal construct

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7408027B1 (en) * 1991-12-06 2008-08-05 Max-Planck-Gesellschaft Zur Forderung Der Wissenchaften Tools for the diagnosis and treatment of Alzheimer's disease
WO1994013795A1 (en) * 1992-12-14 1994-06-23 N.V. Innogenetics S.A. Monoclonal antibodies directed against the microtubule-associated protein tau, hybridomas secreting these antibodies, antigen recognition by these monoclonal antibodies and their applications
US7427392B1 (en) * 1994-11-14 2008-09-23 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau
US20020086009A1 (en) * 1996-03-13 2002-07-04 Koichi Ishiguro Anti-phosphorylated tau protein antibodies and methods for detecting alzheimer`s disease with the use of the same
AU5508798A (en) * 1996-11-19 1998-06-10 Trustees Of The University Of Pennsylvania, The Diagnostic and therapeutic reagents for alzheimer's disease
JP2004503747A (ja) * 2000-07-11 2004-02-05 モレキュラー ジェリアトリクス コーポレイション 結合物質の同定するための試薬と方法
AU2003292936A1 (en) 2002-12-24 2004-07-22 Neurochem (International) Limited Therapeutic formulations for the treatment of beta-amyloid related diseases
US8663650B2 (en) * 2003-02-21 2014-03-04 Ac Immune Sa Methods and compositions comprising supramolecular constructs
EP1494000A1 (en) * 2003-07-02 2005-01-05 Sicpa Holding S.A. Method of marking a material with ions already comprised in said material and method of verifying the authenticity of said material
US20050261475A1 (en) * 2004-02-13 2005-11-24 Harvard Medical School Solid-phase capture-release-tag methods for phosphoproteomic analyses
HUE025186T2 (en) * 2004-02-20 2016-02-29 Ac Immune Sa Methods and methods using supramolecular constructs
KR101152557B1 (ko) * 2005-12-12 2012-09-07 에이씨 이뮨 에스.에이. 치료 백신
US8012936B2 (en) * 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
WO2008140639A2 (en) * 2007-02-08 2008-11-20 Oligomerix, Inc. Biomarkers and assays for alzheimer's disease
UA107571C2 (xx) * 2009-04-03 2015-01-26 Фармацевтична композиція

Similar Documents

Publication Publication Date Title
JP2012520852A5 (enExample)
JP2021501147A5 (enExample)
JP2015221809A5 (enExample)
Johns et al. Myelin oligodendrocyte glycoprotein induces a demyelinating encephalomyelitis resembling multiple sclerosis.
RU2011141889A (ru) Способ для применения в терапии
Schneeberger et al. Vaccination for Parkinson's disease
JP2012522754A5 (enExample)
JP6029280B2 (ja) D−ペプチドを有する抗−アミロイドβ−ペプチド抗体を製造するための組成物
JP2014502141A5 (enExample)
JP2023071688A (ja) リン酸化タウペプチドの組成物およびその使用
JP2012530055A5 (enExample)
JP2022529529A5 (enExample)
JP2017531613A5 (enExample)
JP2009519915A5 (enExample)
JP2017521064A5 (enExample)
JP2008506665A5 (enExample)
JP5474807B2 (ja) 改変アミロイドβペプチド
TW202045204A (zh) 安全投予磷酸化Tau胜肽疫苗的方法
JP2017537926A5 (enExample)
CN114173812A (zh) Tau疫苗的异源给予
Davtyan et al. Immunogenicity of DNA-and recombinant protein-based Alzheimer disease epitope vaccines
JP2019530441A5 (enExample)
JP2016526044A5 (enExample)
EP2300494A1 (en) Anti-amyloid immunogenic compositions, methods and uses
CA3095983A1 (en) Anti-abeta therapeutic vaccines